ArticleMolecular cancer therapeutics2014
Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.
Article in Molecular cancer therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging.ChemMedChem · 2026Article
- Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Chemical biology fluorescent tools forRSC advances · 2023Article
- A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.European journal of nuclear medicine and molecular imaging · 2021Article
- PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Fluorescence-guided resection of tumors in mouse models of oral cancer.Scientific reports · 2020Article
- Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.Nature biomedical engineering · 2020Article
- Frontiers in Intravital Multiphoton Microscopy of Cancer.Cancer reports (Hoboken, N.J.) · 2020Review
- Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.Bulletin of mathematical biology · 2019Article
- PET Imaging of PARP Expression UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology.Trends in biochemical sciences · 2019Review
- Article
- Article
- Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening.Molecular pharmaceutics · 2018Article
- Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.Scientific reports · 2018Article
- Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging.Nature protocols · 2017Article
- Molecular Imaging of PARP.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Imaging of anticancer drug action in single cells.Nature reviews. Cancer · 2017Review
- Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.Cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The heterogeneous delivery of drugs in tumors is an established process contributing to variability in treatment outcome. Despite the general acceptance of variable delivery, the study of the underlying causes is challenging, given the complex tumor microenvironment including intra- and intertumor heterogeneity. The difficulty in studying this distribution is even more significant for small-molecule drugs where radiolabeled compounds or mass spectrometry detection lack the spatial and temporal resolution required to quantify the kinetics of drug distribution in vivo. In this work, we take advantage of the synthesis of fluorescent drug conjugates that retain their target binding but are designed with different physiochemical and thus pharmacokinetic properties. Using these probes, we followed the drug distribution in cell culture and tumor xenografts with temporal resolution of seconds and subcellular spatial resolution. These measurements, including in vivo permeability of small-molecule drugs, can be used directly in predictive pharmacokinetic models for the design of therapeutics and companion imaging agents as demonstrated by a finite element model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.